title: Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
abstract: Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of extranodal lymphomas involving the skin. Diagnosis of the two main subtypes of CTCL-mycosis fungoides (MF) and Sézary syndrome (SS)-is based on the International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer (ISCL/EORTC) classification system, which utilizes clinical, histopathological, molecular biologic, and immunopathologic features. Risk stratification, based on TNMB (tumor, node, metastasis, and blood) staging, provides prognostic information, with limited-stage disease conferring the longest median overall survival. Skin-directed therapies are preferred in the management of limited-stage disease, whereas advanced-stage disease requires systemic therapies. As the mechanisms of CTCL pathogenesis are increasingly understood, new monoclonal antibodies, checkpoint inhibitors, immunomodulatory agents, and small molecules are under investigation and may provide additional therapeutic options for those with advanced CTCL. This review examines the current landscape of targeted therapies in the treatment of CTCLs.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 3A17 N. Ingalis Bldg, 300 N. Ingalis St. SPC 5419, Ann Arbor, MI, 48109-5419, USA. sdevata@med.umich.edu.
authors.forename: Sumana
authors.initials: S
authors.lastname: Devata
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, 4310 CC, Ann Arbor, MI, 48109-5936, USA.
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Wilcox
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D049109:Cell Proliferation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods*; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009367:Neoplasm Staging; D010789:Phototherapy / Q000379:methods; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D015398:Signal Transduction; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D013601:T-Lymphocytes / Q000502:physiology; D059016:Tumor Microenvironment
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D011948:Receptors, Antigen, T-Cell